Table S4.
Clinicopathological parameters in relation to SLC50A1 mRNA expressiona
| Parameters | nb | SLC50A1 high, n (%) | SLC50A1 low, n (%) | P-valuec |
|---|---|---|---|---|
| Total | 20 | 11(55.0) | 9 (45.0) | – |
| Age, years | 0.653 | |||
| <55.5 | 9 | 4 (44.4) | 5 (55.6) | |
| ≥55.5 | 11 | 7 (63.6) | 4 (36.4) | |
| Histological graded | 0.336 | |||
| G1-2 | 14 | 9 (64.3) | 5 (35.7) | |
| G3 | 6 | 2 (33.3) | 4 (66.7) | |
| Lymph node statuse | 0.319 | |||
| pN0 | 15 | 7 (46.7) | 8 (53.3) | |
| pN1-3 | 5 | 4 (80.0) | 1 (20.0) | |
| Distant metastasise | 1.000 | |||
| pM0 | 18 | 9 (50.0) | 9 (50.0) | |
| pM1 | 2 | 1 (50.0) | 1 (50.0) | |
| TNM stagee | 1.000 | |||
| I–II | 17 | 8 (50.9) | 9 (49.1) | |
| III–IV | 3 | 2 (66.7) | 1 (33.3) | |
| Estrogen receptor status | 1.000 | |||
| Negative (IRSf 0–2) | 6 | 3 (50.0) | 3 (50.0) | |
| Positive (IRSf 3–12) | 14 | 8 (57.1) | 6 (42.9) | |
| Progesterone receptor status | 0.319 | |||
| Negative (IRSf 0–2) | 5 | 4 (80.0) | 1 (20.0) | |
| Positive (IRSf 3–12) | 15 | 7 (46.7) | 8 (53.3) | |
| HER2 statusg | 0.591 | |||
| Negative | 16 | 8 (50.0) | 8 (50.0) | |
| Positive | 4 | 3 (75.0) | 1 (25.0) |
Notes:
a
SLC50A1 high expression: > median primary breast cancer expression.
b
Female patients with primary, unilateral breast cancer were included.
c
Fisher’s exact test.
d
According to Bloom and Richardson and modified by Elston and Ellis.1
e
According to UICC TNM classification in breast cancer.2
f
IRS according to Remmele and Stegner.3
g
Overexpression of the ERBB2 gene (Her-2/neu) was diagnosed to the threshold of the DAKO score system based on the IHC assay. Uncertain cases were additionally validated by the FISH assay.
Abbreviations: FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; IRS, immunoreactive score.